tiprankstipranks
Trending News
More News >
Atricure, Inc. (ATRC)
:ATRC
US Market
Advertisement

Atricure (ATRC) Earnings Dates, Call Summary & Reports

Compare
374 Followers

Earnings Data

Report Date
Oct 29, 2025
After Close (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
-0.11
Last Year’s EPS
-0.17
Same Quarter Last Year
Based on 7 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Jul 29, 2025|
% Change Since: 10.62%|
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter with significant revenue growth across multiple segments and successful completion of a major clinical trial enrollment. However, there were challenges noted in the hybrid therapy segment due to competitive pressures and a slight decrease in gross margin. Despite these challenges, the overall performance and strategic direction remain positive.
Company Guidance -
Q3 2025
During the second quarter of 2025, AtriCure reported impressive financial results, with total revenue reaching $136 million, reflecting a 17% year-over-year increase. The company achieved over $15 million in adjusted EBITDA and generated nearly $18 million in cash. Notable product launches such as the AtriClip FLEX Mini and cryoSPHERE MAX significantly contributed to this growth, particularly in appendage management and pain management, with the latter growing nearly 43% in the quarter. The company completed enrollment in the LeAAPS clinical trial, the largest global medical device trial in cardiac surgery, and began testing their PFA device for cardiac surgery. AtriCure projects annual revenue for 2025 to be between $527 million and $533 million, with an adjusted EBITDA of approximately $49 million to $52 million, and an adjusted loss per share ranging from $0.34 to $0.39.
Record Revenue Growth
Achieved total revenue of $136 million, reflecting a 17% year-over-year increase. This growth was broad-based across all franchises.
Strong Performance in Appendage Management
Worldwide revenue for appendage management grew over 20%, driven by open left atrial appendage management growth of 29%.
Pain Management Franchise Expansion
Pain Management grew nearly 43% in the quarter, driven by sales of cryoSPHERE MAX and cryoSPHERE+ probes.
Completion of LeAAPS Clinical Trial Enrollment
Completed enrollment in the LeAAPS clinical trial, the largest global medical device clinical trial in cardiac surgery, with over 6,500 patients.
Positive Cash Generation
Generated nearly $18 million in cash during the second quarter, ending with $117.8 million in cash and investments.

Atricure (ATRC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ATRC Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Oct 29, 2025
2025 (Q3)
-0.11 / -
-0.17
Jul 29, 2025
2025 (Q2)
-0.17 / -0.13
-0.1723.53% (+0.04)
Apr 29, 2025
2025 (Q1)
-0.23 / -0.14
-0.2850.00% (+0.14)
Feb 12, 2025
2024 (Q4)
-0.20 / -0.33
-0.21-57.14% (-0.12)
Oct 29, 2024
2024 (Q3)
-0.20 / -0.17
-0.215.00% (+0.03)
Jul 30, 2024
2024 (Q2)
-0.17 / -0.17
-0.11-54.55% (-0.06)
May 01, 2024
2024 (Q1)
-0.23 / -0.28
-0.14-100.00% (-0.14)
Feb 15, 2024
2023 (Q4)
-0.23 / -0.21
-0.09-133.33% (-0.12)
Nov 01, 2023
2023 (Q3)
-0.30 / -0.20
-0.2725.93% (+0.07)
Jul 25, 2023
2023 (Q2)
-0.30 / -0.11
-0.3265.63% (+0.21)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ATRC Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Jul 29, 2025
$31.73$35.13+10.72%
Apr 29, 2025
$34.65$29.91-13.68%
Feb 12, 2025
$42.36$39.59-6.54%
Oct 29, 2024
$29.43$34.83+18.35%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Atricure, Inc. (ATRC) report earnings?
Atricure, Inc. (ATRC) is schdueled to report earning on Oct 29, 2025, After Close (Confirmed).
    What is Atricure, Inc. (ATRC) earnings time?
    Atricure, Inc. (ATRC) earnings time is at Oct 29, 2025, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ATRC EPS forecast?
          ATRC EPS forecast for the fiscal quarter 2025 (Q3) is -0.11.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis